




RealRate

PHARMACEUTICAL 2025

Actinium Pharmaceuticals Inc
Rank 120 of 225



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Actinium Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Actinium Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 58% points. The greatest weakness of Actinium Pharmaceuticals Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 115% points.

The company's Economic Capital Ratio, given in the ranking table, is 193%, being 22% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	74,506
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,148
Liabilities, Non-Current	35,984
Other Assets	2,029
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	9.0
Other Net Income	3,878
Other Revenues	0
Property and Equipment	364
Research and Development	30,045
Selling, General and Administrative Expense	12,076

Output Variable	Value in 1000 USD
Assets	76,899
Liabilities	44,141
Expenses	42,121
Revenues	0
Stockholders Equity	32,758
Net Income	-38,243
Comprehensive Net Income	-38,243
BaseVar	83,520
ECR before LimitedLiability	55%
Economic Capital Ratio	193%